Use of apomorphine as a therapeutic agent for necroptosis-related diseases
Apomorphine is used to inhibit necroptosis by binding to MLKL, addressing the lack of therapeutic agents for necroptosis-related diseases and improving symptoms of inflammatory and neurodegenerative conditions.
Patent Information
- Application Number
- JP2024525975
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-02
- Filing Date
- 2022-11-02
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a lack of effective therapeutic agents for necroptosis-related diseases, which are characterized by inflammatory and neurodegenerative conditions, due to insufficient understanding of the molecular targets and signal transduction systems involved in necroptosis.
Apomorphine, an FDA-approved drug for treating Parkinson's disease, is identified to inhibit necroptosis by specifically binding to and inhibiting the formation of MLKL (mixed lineage kinase domain-like pseudokinase) pores, thereby preventing programmed cell death.
Apomorphine effectively inhibits necroptosis, reducing inflammation and improving symptoms of diseases such as inflammatory bowel disease and neurodegenerative disorders by blocking MLKL oligomerization and membrane pore formation.
Smart Images

Figure 2024542061000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to apomorphine and uses thereof for treating necroptosis-associated diseases, and more particularly to a pharmaceutical composition for preventing or treating necroptosis-associated diseases, comprising apomorphine or a pharma- ceutical acceptable salt thereof as an active ingredient, and a method for producing the same. [Background technology]
[0002] Appropriate cell death is one of the cellular functions that is very important in the life of living organisms, and inappropriate cell death is closely related to human diseases such as cancer, degenerative diseases, immune diseases, improper development, etc. For this reason, the phenomenon of cell death and the phenomenon of regulating cell death, as well as human diseases caused by improper regulation and the development of treatments to overcome them, are well known as the most extensively researched fields in the field of life science.
[0003] Generally, there are two types of cell death: necrosis and apoptosis. Natural cell death is programmed cell death that is regulated by development and physiological cell turnover. Necrosis is direct and rapid cell death caused by external physical and chemical stress (heat, osmotic pressure, pressure, shock due to temperature difference, etc.). This type of necrosis is unregulated and caused by unprogrammed accidental causes, and is characterized by the loss of cell membrane and cell collapse. In addition, when the cell membrane is lost, substances within the cell cause inflammation. However, recent research results have revealed that necrosis is not a cell death caused by accident, but a cell death mechanism that is programmed like apoptosis, and the term necroptosis (or programmed necrosis) was created to explain this.
[0004] Necroptosis is a programmed cell death mode. Most research on cell death has focused on apoptosis, which is a type of programmed cell death. Since the discovery of the enzyme caspase, many pharmaceutical companies have been developing drugs using caspase inhibitors for the past decade. However, there are still very few drugs approved by the FDA, because apoptosis is a type of cell death that occurs under physiological conditions and is likely due to a defense mechanism that maintains homeostasis in the body.
[0005] In contrast, necroptosis is a cell death that occurs primarily in pathological situations and is almost always characterized by an inflammatory response, and ischemic, neurodegenerative, and inflammatory diseases are representative of necroptosis-induced diseases.
[0006] Necroptosis is an unregulated accidental death under pathological conditions, and its mechanism of action, molecular targets, signal transduction system, etc. have hardly been studied. Therefore, it is extremely urgent to discover and develop such a necroptosis inhibitor in order to treat diseases caused by necroptosis and to clarify the biological and pathological causes of necroptosis. However, no suitable therapeutic agent for such necroptosis diseases has yet been reported.
[0007] On the other hand, apomorphine (APO) has the chemical formula C 17 H 17 NO 2Apomorphine is a compound that is a derivative of a narcotic drug synthesized by reacting morphine with a strong mineral acid, and is an FDA-approved drug that is routinely used to treat Parkinson's disease through the activation of dopamine D2-like receptors. It is structurally similar to dopamine and acts by stimulating dopamine autoreceptors located in dopaminergic neurons. Specifically, apomorphine activates dopamine receptors in the nigrostriatal pathway, limbic system, hypothalamus, and pituitary gland, inducing effects such as improved motor function.
[0008] The prior art has used apomorphine to induce emesis, treat erectile dysfunction, and treat Parkinson's disease. Apomorphine is also used as a therapeutic agent for myocardial infarction (see Patent Document 0001), for neurodegenerative diseases such as motor neuron disease, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), primary lateral sclerosis (PLS), Huntington's disease, Alzheimer's disease, Parkinson's disease, and age-related macular degeneration (see Patent Document 0002), and for ischemic diseases such as ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic-ischemic encephalopathy, and for ischemic cerebral thrombosis, which are ischemic diseases. There are prior documents disclosing that apomorphine can be used as a therapeutic agent for treating peripheral ischemia, ischemic cardiac disease, ischemic enteropathy, peripheral ischemia disease, and ischemic reperfusion induced arrhythmias (see Patent Document 0003), but none of these documents clarify the necroptosis death inhibitory effect of apomorphine. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] CN Publication Patent No. 105753879 A [Patent Document 2] US Published Patent No. 2021-0214310 A1 [Patent Document 3] US Published Patent No. 7294715 B2 Summary of the Invention [Problem to be solved by the invention]
[0010] An object of the present invention is to provide a drug that has the function of inhibiting necroptosis.
[0011] Another object of the present invention is to provide a drug having therapeutic efficacy for necroptosis-related diseases. [Means for solving the problem]
[0012] In order to achieve the above object, the present inventors conducted drug screening to identify substances that have the function of inhibiting necroptosis, and as a result, revealed the necroptosis inhibitory function of apomorphine and its therapeutic efficacy for necroptosis-related diseases.
[0013] Therefore, the present invention provides a pharmaceutical composition for preventing or treating a necroptosis-associated disease, which comprises apomorphine or a pharma- ceutical acceptable salt thereof as an active ingredient. Effect of the Invention
[0014] The present invention provides a pharmaceutical composition containing apomorphine as an active ingredient, which can be usefully used for the prevention and treatment of necroptosis-related diseases. [Brief description of the drawings]
[0015] [Figure 1a] Figure 1a is a graph showing the amount of PI (propidium iodide) absorbed when TBZ + apomorphine (APO) was treated in human mononuclear cell line THP-1 cells. Data are shown as the average of two experiments. (TBZ: TNF-α (ATGen, TNF0501) + BV6 (Biovision, B1332-5) + Z-VAD (invivoGen, tlrl-vad)) [Figure 1b]1b is a photograph and a graph showing changes in phosphorylation of MLKL by Western blot when THP-1 cells were treated with TBZ+APO. Data are shown as the average of two independent experiments. [Figure 1c] Figure 1c shows photographs of TBZ-, necrostatin-1 (NEC-1-), and APO-treated cells fractionated into cytoplasmic and crude membrane fractions, followed by Western blotting of samples with the indicated antibodies. LDH is a cytoplasmic marker, LAMP1 is a membrane marker, and data are presented as the average of two independent experiments. [Figure 1d] FIG. 1d is the IC50 graph curve for apomorphine treatment. [Figure 2a] Figure 2a shows that cells treated with each molecule for the indicated times were separated into cytoplasmic and membrane fractions and analyzed by non-reducing or reducing SDS-PAGE followed by probing with specific antibodies. LDH is a cytoplasmic marker and LAMP1 is a membrane marker. [Figure 2b] Figure 2b is a photograph showing the time course of MLKL oligomerization after induction of necrosis analyzed by non-reducing or reducing SDS-PAGE. [Figure 3a] FIG. 3a shows photographs of transfected THP-1 cells treated with TBZ, NEC-1, or APO, stained with DAPI and Alexa 488, and then observed using a confocal microscope. [Figure 3b] Figure 3b shows the fold increase in membrane / cytoplasmic signal intensity of Flag-MLKL (Scale bar, 5 μm, mean ± SEM, **p<0.01, ***p<0.001 vs. TBZ alone, One-way ANOVA). [Figure 4] Figure 4 shows the photographs and graphs of TBZ-treated THP-1 cells treated with APO in a concentration-dependent manner (1, 5, 20, 80, 320 μM), and then the supernatant was concentrated and analyzed by Western blotting with an HMGB1 antibody. Data are shown as the average of three independent experiments (mean ± SEM, ***p<0.001 vs. TBZ alone group, One-way ANOVA.) [Diagram 5]FIG. 5 is a graph showing the surface plasmon analysis of APO (200, 100, 50, 25, 12.5, 6.25, 0 μg / ml) binding to MLKL and the MLKL N-term domain. [Figure 6a] FIG. 6a is a photograph showing the oligomerization of MLKL upon treatment of TBZ-treated THP-1 cells with APO (oxidized and reduced forms) analyzed by non-reducing or reducing SDS-PAGE. [Figure 6b] FIG. 6b is a graph showing the surface plasmon analysis of oxidized and reduced forms of APO (200, 100, 50, 25, 12.5, 6.25, 0 μg / ml) binding to MLKL protein. [Figure 6c] FIG. 6c is a graph of surface plasmon analysis of oxidized and reduced forms of APO (250, 125, 62.5, 31.12, 15.56, 7.88, 3.44, 1.72, 0.86, and 0 μg / ml) binding to the MLKL N-term domain. [Figure 7a] Figure 7a shows the effects of APO injection (0.15, 1.5, 15 mg / kg) on histopathology and mucosal material changes in mouse colon and the HI score. (Scale bar, 100 μm, mean ± SD (n=5). *p<0.05, ***p<0.001, One-way ANOVA.) [Figure 7b] Figure 7b is a photograph and a graph showing the colon length of each group. (Mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA.) [Figure 7c] Figure 7c is a graph showing the evaluation of the disease activity index (DAI) of colitis. NEC-1 was used as an inhibitor control group. (Mean ± SD (n = 5). *p < 0.05, ***p < 0.001, t-test.) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The present invention relates to a pharmaceutical composition for preventing or treating a necroptosis-associated disease, comprising apomorphine as an active ingredient.
[0017] The term "necroptosis" as used herein means programmed cell death, necroptosis, cell death, and necrosis. Necroptosis leads to the release of damage-associated molecular patterns (DAMPs), and the DAMPs in the extracellular environment are typically HMGB1, which induces activation of the immune system and induces inflammation. Necroptosis, which is the programmed cell death of cells, is carried out through sequential signaling of RIP1, RIP3, and MLKL in the cytoplasm, and the MLKL molecule, which is the last step, is oligomerized in the cell membrane upon phosphorylation to form pores in the cell membrane. Specifically, phosphorylated MLKL (p-MLKL) forms a tetramer through oligomerization. Two tetramers interact to form an octamer, and pores are formed in the cell membrane. For more detailed information in this regard, one may further refer to Sun L, et al. Trends Biochem Sci. 2014 Dec;39(12):587-93. doi:10.1016 / j.tibs.2014.10.003. PMID:25455759.
[0018] In this regard, the present invention confirmed that apomorphine has the specificity to specifically inhibit the formation of cell membrane pores of MLKL (mixed lineage kinase domain like pseudokinase), the terminal mediator of necroptosis.
[0019] Apomorphine of the present invention undergoes an oxidation reaction and increases its direct binding to MLKL, thereby inhibiting MLKL oligomerization, and ultimately inhibiting necroptosis.
[0020] Thus, the present invention provides a novel use of apomorphine for the prevention or treatment of necroptosis-related diseases.
[0021] Necroptosis-related diseases of the present invention include ischemic, neurodegenerative, and inflammatory diseases. Specifically, the necroptosis-related diseases include stroke, autoimmune disease, inflammatory bowel disease (IBD), sepsis, chronic obstructive pulmonary disease, acute respiratory distress disorder, transfusion-related acute lung injury, transplant rejection, atherosclerosis, aortic aneurysm, myocardial infarction, terminal ileitis, acute kidney injury, renal ischemia reperfusion injury, liver injury, steatohepatitis, pancreatitis, bone marrow failure, and the like. Related content: Khoury MK, Gupta K, Franco SR, Liu B.Necroptosis in the Pathophysiology of Disease.Am J Pathol.2020 Feb;190(2):272-285.doi:10.1016 / j.ajpath.2019.10.012.Epub 2019 Nov 26.PMID:31783008;PMCID:PMC6983729;Ware LB.Transfusion-induced lung endothelial injury:a DAMP death? Am J Respir Crit Care Med.2014 Dec 15;190(12):1331-2.doi:10.1164 / rccm.201411-2047ED.PMID:25496097.;Leeper NJ.The role of necroptosis in atherosclerotic disease.JACC Basic Transl Sci.2016 Oct;1(6):548-550.doi:10.1016 / j.jacbts.2016.08.002.PMID:28480338;PMCID:PMC5419689.;Gunther C,Martini E,Wittkopf N,Amann K,Weigmann B,Neumann H,Waldner MJ,Hedrick SM,Tenzer S,Neurath MF,Becker C.Caspase-8 regulates TNF-α-induced pithelial necroptosis and terminal ileitis.Nature.2011 Sep 14;477(7364):335-9.doi:10.1038 / nature10400.PMID:21921917;PMCID:PMC3373730.;Jun W,Benjanuwattra J,Chattipakorn SC,Chattipakorn N.Necroptosis in renal ischemia / reperfusion injury:A major mode of cell death?Arch Biochem Biophys.2020 Aug 15;689:108433.doi:10.1016 / j.abb.2020.108433.Epub 2020 May 26.PMID:32470461.;Gautheron J,Vucur M,Luedde T.Necroptosis in Nonalcoholic Steatohepatitis.Cell Mol Gastroenterol Hepatol.2015 Mar 12;1(3):264-265.doi:10.1016 / j.jcmgh.2015.02.001.PMID:28210679;PMCID:PMC5301189.;Roderick JE,Hermance N,Zelic M,Simmons MJ,Polykratis A,Pasparakis M,Kelliher MA.Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc Natl Acad Sci US A. 2014 Oct 7;111(40):14436-41. doi:10.1073 / pnas.1409389111. Epub 2014 Sep 22. PMID:25246544; PMCID:PMC4209989. may be further referenced.
[0022] The inflammatory bowel disease may include Crohn's disease or ulcerative colitis. The autoimmune disease may include psoriasis or rheumatoid arthritis.
[0023] The present inventors demonstrated through the DSS-induced colitis experiment in the following Example that apomorphine is effective in improving the symptoms of inflammatory bowel disease.
[0024] Therefore, the present invention provides a pharmaceutical composition for preventing or treating a necroptosis-associated disease, which contains apomorphine or a pharma- ceutical acceptable salt thereof as an active ingredient, use of apomorphine or a pharma- ceutical acceptable salt thereof for the manufacture of a pharmaceutical composition for preventing or treating a necroptosis-associated disease, and a method for preventing or treating an apoptosis-associated disease, which comprises administering a therapeutically effective amount of apomorphine or a pharma- ceutical acceptable salt thereof to a subject.
[0025] In the present invention, pharma- ceutically acceptable salts can be prepared by a method commonly used in the art, and include, for example, inorganic acid salts such as hydrochloric acid, bromic acid, sulfuric acid, sodium hydrogen sulfate, phosphoric acid, nitric acid, and carbonic acid, organic acid salts such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, tartaric acid, gluconic acid, lactic acid, gentisic acid, fumaric acid, lactobionic acid, salicylic acid, trifluoroacetic acid, and acetylsalicylic acid (aspirin), amino acid salts such as glycine, alanine, vanillin, isoleucine, serine, cysteine, cystine, aspartic acid, glutamine, lysine, arginine, tyrosine, and proline, sulfonates such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid, metal salts obtained by reaction with alkali metals such as sodium and potassium, and salts with ammonium ions. There is no particular limitation on the pharma-ceutically acceptable salts, so long as they can be used in medicines.
[0026] In one embodiment of the present invention, apomorphine may be in the form of a salt. Without being limited thereto, the pharmaceutical composition of the present invention may contain apomorphine hydrochloride as an active ingredient. More specifically, in the present invention, apomorphine may be apomorphine hydrochloride hemihydrate.
[0027] The pharmaceutical composition of the present invention contains at least one pharma- ceutically acceptable carrier in addition to the active ingredient. As used herein, the term "pharma-ceutically acceptable carrier" refers to a known pharmaceutical additive that is useful in formulating a pharma- ceutical active compound for administration and is essentially non-toxic and non-sensitive under the conditions of use. The exact proportion of such excipients is determined by the solubility and chemical properties of the active compound, the chosen route of administration, as well as standard pharmaceutical practice.
[0028] The pharmaceutical composition of the present invention may be formulated into a form suitable for the desired administration method using suitable and physiologically acceptable excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glidants, flavoring agents and other additives.
[0029] The pharmaceutical composition may be formulated in the form of, but is not limited to, a tablet, capsule, pill, granule, powder, injection, film or liquid.
[0030] The dosage form and pharma- ceutically acceptable carrier of the pharmaceutical composition may be appropriately selected by techniques known in the art, and may refer to, for example, the following documents: [Urquhart et al., Lancet, 16:367, 1980]; [Lieberman et al., PHARMACEUTICAL DOSAGE FORMS-DISPERSE SYSTEMS, 2nd ed., vol. 3, 1998]; [Ansel et al., PHARMACEUTICAL DOSAGE FORMS & DRUG DELIVERY SYSTEMS, 7th ed., 2000]; [Martindale, THE EXTRA PHARMACOPEIA, 31st ed.]; [Remington's PHARMACEUTICAL SCIENCES, 16th-20th editions]; [THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, Goodman and Gilman, eds., 9th ed., 1996]; [Wilson and Gisvolds' TEXTBOOK OF ORGANIC MEDICINAL AND PHARMACEUTICAL CHEMISTRY, Delgado and Remers, eds., 10th ed., 1998. For the principles of formulating pharmaceutical compositions, the following documents may be referred to: Platt, Clin Lab Med, 7:289-99, 1987; Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Churchill Livingstone, NY, 1988; EXTEMPORANEOUS ORAL LIQUID DOSAGE PREPARATIONS, CSHP, 1998; and "Drug Dosage," J Kans Med Soc, 70(1):30-32, 1969.
[0031] In one embodiment, the pharmaceutical composition of the present invention may be formulated as an injection, but is not limited thereto. The injection may be formulated as an intravenous injection or subcutaneous injection. In the case of a parenteral injection, it may contain components contained in a general injection composition. For example, the injection composition may contain a liquid carrier such as sterile water, water for injection, or physiological saline. In addition, it may further contain at least one component selected from the group consisting of amino acids, sugars, lipids, vitamins, electrolytes, pH adjusters, stabilizers, osmotic pressure adjusters, and solubilizers.
[0032] Currently, apomorphine has been developed as a subcutaneous injection and is commercially available under the trade name "Apokyn". Apokyn has been developed to be subcutaneously injected 3 to 5 times a day, and the pharmaceutical composition of the present invention may also be formulated as a dosage form such as Apokyn as necessary. For example, the pharmaceutical composition of the present invention may be a subcutaneous injection, and in this case, in addition to apomorphine, it may contain sodium metabisulfite, benzyl alcohol, hydrochloric acid, sodium hydroxide, etc. as additives.
[0033] In one embodiment, the pharmaceutical composition of the present invention may be formulated as a sublingual tablet or a film. When the composition is formulated as a tablet, it may further comprise at least one component selected from the group consisting of excipients, binders, disintegrants, lubricants, solvents, antioxidants, emulsifiers, thickeners, anti-caking agents, flavoring agents, coloring agents, sweeteners, pH adjusters, sustained-release agents, stabilizers, and coating agents. In one embodiment of the present invention, the additives may include, but are not limited to, sodium edetate, ascorbic acid, magnesium stearate, hypromellose, citric acid, microcrystalline cellulose, colloidal silicon dioxide, cool mint orange (WONF WL-28499), red 30 iron oxide (E172), acesulfame potassium, and mannitol.
[0034] When the composition is formulated as a film, it may further comprise binders, stabilizers, antioxidants, chelating agents, thickeners, coating agents, flavoring agents, sweeteners, and pH adjusters.The additives may include, but are not limited to, sodium metabisulfite, disodium EDTA, dihydrate, glycerol, glyceryl monostearate, hydroxyethylcellulose, hypromellose, maltodextrin, (-)-menthol, pyridoxine hydrochloride, sodium hydroxide, sucralose, and white ink.
[0035] The preferred dosage of the composition of the present invention varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. However, for a favorable effect, the composition of the present invention can be administered at a dose of 100 μg to 200 mg, for example, 200 μg to 100 mg, for example, 2 mg to 6 mg. The administration may be once a day or in several divided doses. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
[0036] In the present invention, the term "subject" refers to a subject in need of prevention or treatment of a disease, and more specifically, refers to a mammal such as a human or non-human primate, mouse, dog, cat, horse, or cow in need of prevention or treatment of a necroptosis-related disease.
[0037] The compositions of the invention may be administered by various routes, for example, orally, transdermally, sublingually, rectally or intravenously, intramuscularly, subcutaneously, intranasally, intrauterine dura or intracerebroventricular, although all modes of administration are foreseeable.
[0038] In a preferred embodiment of the invention, the pharmaceutical composition may be administered by subcutaneous injection.
[0039] The advantages and features of the present invention, as well as the methods for achieving them, will become apparent from the following detailed examples. However, the present invention is not limited to the following examples, and may be embodied in various different forms. However, the following examples are provided to fully disclose the present invention and to fully inform those skilled in the art of the present invention of the category of the invention, and the present invention is only defined by the category of claims. EXAMPLES
[0040] Experimental Method 1-1. Cell lines, culture and transfection Human monocytic cell line THP-1 and human colon cancer cell line HT-29 were cultured in 10% FBS-Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 2 mM L-glutamine, 100 U / ml penicillin, and 100 μg / ml streptomycin at 37°C and 5% CO. 2 THP-1 cells were differentiated into macrophages in RPMI 1640 medium containing 500 nM phorbol 12-myristate 13-acetate (PMA) for 3 h. Human mixed lineage kinase domain-like protein (MLKL)-Flag plasmid (Sino biological, HG12810-CF) transfection was performed using the MicroPorator-mini (Digital Bio) electroporation system (Invitrogen).
[0041] 1-2.Animal experiments Animal experiments were performed on 6-8 week-old male C57BL / 6 mice according to procedures approved by the Yonsei University School of Medicine Animal Laboratory Animal Care and Use Committee (YLARC, 2018-0024). Mice were housed in polypropylene cages with a maximum of four mice per cage under constant temperature and humidity, and the light / dark cycle was changed every 12 h. All mice were given an adaptation period of at least 7 days before participation.
[0042] 1-3. Mouse model of DSS-induced colitis For dextran sulfate sodium (DSS, 36-50 kDa, MP Biomedicals)-induced colitis, mice were administered 2.5% DSS in drinking water for 7 days. Mice were randomly divided into eight groups:
[0043] 1) Control group 2) Apomorphine treatment (=APO; STK088477, Vitas-M, 1.5 mg / kg, daily intraperitoneal injection) 3) APO treatment (15 mg / kg, daily intraperitoneal injection) 4) DSS processing 5) DSS and necrostatin-1 (NEC-1; Biovision, 1864-5, 1.5 mg / kg, daily intraperitoneal injection) 6) DSS and APO (0.15 mg / kg, daily intraperitoneal injection) 7) DSS and APO (1.5 mg / kg, daily intraperitoneal injection) 8) DSS and APO (15 mg / kg, daily intraperitoneal injection)
[0044] Body weight and disease activity index (DAI) scores of mice were recorded daily. DAI was calculated by adding the scores of body weight loss (0=none, 1=1%-5% body weight loss, 2=5%-10% body weight loss, 3=10%-15% body weight loss, 4=15% or more body weight loss), stool consistency / diarrhea (0=normal, 2=watery stool, 4=watery diarrhea) and bleeding (0=no bleeding, 2=slight bleeding, 4=total bleeding). At the end of the experiment, mice were sacrificed and their colons were removed to confirm the change in colon length and to measure body weight loss.
[0045] In this experiment, NEC-1 was used as a substance that inhibited RIP1 phosphorylation and was used as a control group to confirm the effect of apomorphine.
[0046] 1-4. Preparation of tissue samples After the experiment was completed, the mice were sacrificed and the colon (without the cecum) was removed. The removed colon was washed with cold phosphate-buffered saline (PBS; Wellgene, LB001-02) before length measurement. The measured colon was prepared for further analysis by cutting the intestinal segments along the mesenteric line and washing with PBS. The intestinal segments were then placed in a Petri dish and fixed with modified Bouin's fixative (50% ethanol / 5% acetic acid in dHO). 2 The colon was then fixed in a 500 ml tumbler (O). The lumen side was held with forceps in one hand and a toothpick in the other, the end of the gizzard was held facing upwards, and the flat open end of the colon was pulled with tongs, after which the end of the gizzard was wrapped around the toothpick. The entire colon was wrapped, placed in a cassette, and immersed in 4% paraformaldehyde (Biosesang, PC2031-100-00) overnight at 4°C.
[0047] 1-5. Necroptosis induction Cells were pretreated with Z-VAD (invivoGen, tlrl-vad) and compounds for 1 hour, and then necrosis was induced with TNF-α (ATGen, TNF0501) and BV6 (Biovision, B1332-5) for the indicated times. The prepared cells were appropriately processed according to the assay (Z-VAD: carbobenzoxy-valyl-alanyl-aspartyl, TNF-α: tumor necrosis factor-α, BV6: 4,4'-(1,6-hexanediyl)bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolyl-β-phenyl-L-phenylalaninamide).
[0048] 1-6. Western blot analysis Cells were treated with drug candidates and obtained using centrifugation at 1500xg for 5 min at 4°C. The supernatant was centrifuged again at 1500xg for 5 min at 4°C to remove remaining debris, concentrated using an Amicon ultra-0.5 centrifugal filter unit 10k (Millipore, UFC501096) at 14,000xg for 30 min at 4°C, and stored. The obtained cells were lysed using 1x radioimmunoprecipitation assay (RIPA) buffer (GenDEPOT, R4100-010) containing 1x protease inhibitor (GenDEPOT, P3100-001) and phosphatase inhibitor (Thermo Fisher Scientific, 1862495). The cell lysate was then centrifuged at 20,000xg for 30 min at 4°C to remove debris. The concentration of extracted protein was measured using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, 23225). The concentrated and stored supernatant and extracted protein were subjected to non-reducing or reducing SDS-PAGE (8% to 12%), and the SDS-PAGE gel was transferred to a nitrocellulose membrane. Membranes were blocked with 5% nonfat milk in Tris-buffered saline-1% Tween 20 (TBS-T) and probed with antibodies specific for MLKL (Cell Signaling Technology, 14993S), phospho-MLKL (S358) (Cell Signaling Technology, 91689S), GAPDH (Abfrontier, LF-PA0018), phospho-RIP1 (S166) (Cell Signaling Technology, 65746S), RIP1 (Abcam, ab72139), LDH (Cell Signaling Technology, 2012S), LAMP1 (Abcam, ab24170), and HMGB1 (Abcam, ab92310).
[0049] 1-7. Subcellular fraction The resulting cells were incubated in 10 mM KCl, 1 mM MgCl 2The cells were resuspended in 20 mM Tris (pH 7.4) buffer supplemented with 1X protease inhibitors and phosphatase inhibitors and incubated on ice for 30 min. The cells were passed 30 times through a 22-gauge needle and centrifuged at 500 x g for 15 min. The supernatant was centrifuged again at 20,000 x g for 15 min and saved as the cytoplasmic fraction. The remaining pellet was resuspended in lysis buffer, centrifuged at 20,000 x g for 15 min, and saved as the crude membrane fraction.
[0050] 1-8. Microplate reader for measuring PI (propidium iodide) absorption by stomatal cells Cells were plated in flat, clear-bottom, black-walled 96-well plates, and after 7 h of chemical treatment and induction of necrosis, PI (BD biosciences, 556463) was added at a final concentration of 50 μg / ml. After 10 min of incubation under the original culture conditions, cells were centrifuged at 400×g for 5 min. Real-time fluorescence monitoring was performed with a Varioskan Flash 3001 plate reader, measuring an emission wavelength of 617 nm after excitation at 530 nm. Data collection was performed at 37°C. (Figure 1a)
[0051] 1-9.Immunofluorescent staining Cells were seeded on cell culture treated glass chamber slides. These cells were pretreated with Z-VAD, BV6 and the indicated compounds for 1 h, followed by treatment with TNF-α and BV6 overnight. Cells were then washed with phosphate buffered saline (PBS) and then fixed with 4% paraformaldehyde for 10 min. Cells were washed three more times with PBS before being incubated with 0.25% Triton X-100 in PBS for 10 min. Cells were blocked with 5% bovine serum albumin (BSA) in PBS for 30 min and stained using anti-Flag (Sigma, F7425-2MG) antibody. Nuclei were stained with DAPI (Invitrogen, 00-4959-52). Images were captured using a confocal microscope (Olympus, FV1000).
[0052] 1-10. Surface plasmon resonance (SPR) analysis The interaction of MLKL and apomorphine (=APO) was detected through SPR (Surface Plasmon Resonance) analysis using a GE Healthcare Biacore T200. For pH scouting, a buffer solution consisting of 10 mM sodium acetate at pH 4.0-6.0 was used. For the scouted buffer conditions, MLKL protein (Abcam, ab241453) and laboratory-purified MLKL N-term (1-154 amino acids) protein were immobilized on the surface of a sensor chip CM5 (GE Healthcare). ligand To derive KD values, the coupling process was performed based on the molecular weights of MLKL, MLKL N-terminus domain (MW ligand) and APO (MW analyte). Oxidized (24 hr, RT incubation) and reduced (+DTT (DL-Dithiothreitol)) forms of APO were injected in a running buffer consisting of 10 mM HEPES, pH 7.4, at 25°C (10 μl / min flow rate). Sensorgrams were recorded and analyzed in real time using the control software provided with the Biacore T200 system. More than six concentrations of APO were used for binding, and the respective KD values were derived. All running data were calculated using BIAevaluation Software (GE Healthcare).
[0053] 1-11. Histological evaluation After the experiment, colon tissues collected from sacrificed mice were fixed in 4% paraformaldehyde overnight. Swiss-rolled and fixed colon specimens were embedded in paraffin. 5 μm sections were cut and stained with hematoxylin and eosin (H&E). Histological assessment of colitis lesions along the entire colon length was performed with reference to a scoring system of the degree of crypt structure damage (0–3), the degree of inflammatory cell infiltration (0–3), and submucosal edema (0–3).
[0054] 1-12. Immunohistochemistry (IHC) and Periodic Acid-Schiff (pAS) Paraffin sections cut at 5 μm were blocked with TBS-T supplemented with 5% BSA, and then sections were co-incubated with primary antibodies at 4°C overnight. Secondary antibodies were added and incubated for 1 h. The resulting sections were incubated with DAB (3,3'-diaminobenzidine) kit for 10 min. Periodic Acid Staining (PAS) staining was performed according to standard protocols.
[0055] 1-13.Statistical analysis Experimental data were analyzed using GraphPad Prism. Data are presented as mean, SD, and SEM as indicated in the individual figure legends. Differences were considered statistically significant when *p<0.05, **p<0.01, and ***p<0.001.
[0056] Experimental Example 1: Confirmation of cell membrane pore formation ability upon apomorphine treatment As an initial screening step, PI absorption was measured (Experimental Methods 1-8), and compounds that reduced PI absorption to less than 30% of the signal intensity after TBZ treatment were selected to examine changes in cell membrane integrity.
[0057] After 10 minutes of treatment with PI in TBZ+APO-treated THP-1 cells, the amount of PI absorbed by the cells was measured using a microplate reader. Necrostatin-1 (NEC-1) was used as an inhibitor control. Data are shown as the average of two experiments. (TBZ:TNF-α+BV6+Z-VAD)
[0058] The results showed that apomorphine (APO) effectively reduced PI absorption and reduced the ability of selected compounds to decrease the formation of cell membrane pores (Figure 1a).
[0059] Experimental Example 2: Confirmation of the presence or absence of apomorphine inhibition of MLKL phosphorylation As a secondary screening process, the degree of phosphorylation of MLKL was measured by Western blot for functional analysis (Experimental Methods 1-6, FIG. 1b). Western blotting using the indicated antibodies shows the change in phosphorylation of MLKL in cells treated with TBZ+APO. Data are presented as the average of two independent experiments.
[0060] As a result, APO did not inhibit the phosphorylation of MLKL. That is, as confirmed in Experimental Example 1, APO reduces the formation of cell membrane pores, which indicates that APO inhibits necrosis by affecting the process from MLKL phosphorylation to the formation of cell membrane pores.
[0061] Experimental Example 3: Identification of apomorphine-associated necrotic pathways To determine which step in the necrotic pathway apomorphine affects, TBZ-, NEC-1-, and APO-treated cells were fractionated into cytosolic and crude membrane fractions, and samples were then subjected to Western blotting with the indicated antibodies.
[0062] As a result, the phosphorylation of RIP1 and MLKL, which are mediators of the necrotic pathway, and the transfer of these molecules from the cytoplasm to the membrane fraction were confirmed by the differentiation of the cells into the cytoplasm and the membrane (Fig. 1c).The inhibitory concentration (IC50) of the drug inducing 50% of the maximum inhibition was also determined by measuring the change in cell membrane integrity in a concentration-dependent manner for APO (IC50=5.7 μM) (Fig. 1d).
[0063] Experimental Example 4: Confirmation of apomorphine's inhibition of MLKL oligomerization To test whether the formation of p-MLKL tetramers and octamers for cell membrane pore formation is inhibited by apomorphine (=APO), cells treated with each molecule for the indicated times were separated into cytoplasmic and membrane fractions, analyzed by non-reducing or reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then probed with specific antibodies (Experimental Methods 1-6). Here, LDH (lactate dehydrogenase) is the cytoplasmic marker, and LAMP1 (Lysosomal-associated membrane protein 1) is the membrane marker.
[0064] As a result, it was confirmed that the band intensity of MLKL tetramer and octamer was reduced when APO was treated (Figure 2). In other words, APO inhibits MLKL oligomerization. In particular, in Figure 2b, MLKL oligomerization was confirmed over time after necrosis induction.
[0065] Experimental Example 5: Confirmation of MLKL potential blockade by apomorphine on cell membrane Transfected THP-1 cells were treated with TBZ, NEC-1, or APO and stained with DAPI and Alexa 488. The intracellular location of MLKL was tracked in transfected THP-1 cells via the expression of MLKL-flag protein using confocal microscopy (Experimental Methods 1-9).
[0066] Cells treated with TBZ to induce necrosis showed phosphorylation of MLKL and translocation of p-MLKL to the plasma membrane. Flag-MLKL signals were distributed throughout the cells under physiological conditions, whereas TBZ-treated cells showed a dot-like distribution of Flag-MLKL signals at the plasma membrane.
[0067] Flag-MLKL signals were distributed largely within the cytoplasm of cells stimulated with APO and TBZ, as well as those stimulated with NEC-1, an inhibitor of RIP1 phosphorylation, and TBZ.
[0068] This confirms that APO in the cytoplasm inhibits MLKL from concentrating on the cell membrane.
[0069] Experimental Example 6: Confirmation of inhibition of HMGB1 secretion by concentration-dependent treatment with apomorphine To test whether APO treatment inhibits the secretion of HMGB1, a representative of the damage-associated molecular pattern, one of the characteristics of necrosis, in THP-1 cells in which necrosis was induced by TBZ treatment, APO was treated concentration-dependently (1, 5, 20, 80, 320 μM) for 8 hours, and the supernatant was concentrated and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by investigation with HMGB1 antibody (Experimental Method 1-6). Necrostatin-1 (NEC-1) was used as an inhibitor control, and data are shown as the average of three independent experiments.
[0070] As a result, it was confirmed that the amount of HMGB1 secreted into the supernatant was reduced by APO treatment in a concentration-dependent manner compared to the group treated with TBZ alone (Figure 4), confirming that APO treatment reduces HMGB1 secreted during the necrotic process, thereby inhibiting necrosis.
[0071] Experimental Example 7: Confirmation of necrosis pathway inhibition by apomorphine binding to MLKL The above experimental examples confirmed that APO inhibits p-MLKL oligomerization and inhibits the formation of cell membrane pores. In this example, we confirmed whether APO achieves inhibition through direct binding to MLKL, particularly the MLKL N-term domain.
[0072] To analyze the interaction pattern between APO and MLKL proteins, SPR analysis was used (Experimental Methods 1-10). A KD value of 1.272E-8M was obtained for the binding of MLKL and APO, and a KD value of 6.254E-8M was obtained for the binding of MLKL N-term and APO. Here, the binding of MLKL, MLKL N-term domain protein immobilized on a CM5 chip with six concentrations of APO was analyzed.
[0073] In other words, it was confirmed that when APO was treated, it directly bound to the N-terminus domain of MLKL with high affinity, thereby inhibiting MLKL oligomerization.
[0074] Experimental Example 8: Confirmation of inhibition of MLKL oligomerization by oxidation of apomorphine It is well known that APO spontaneously oxidizes over time in the presence of light and air. In this example, to test whether the degree of oxidation of APO increases its binding to MLKL in cells, thereby decreasing MLKL oligomerization, APO was stored at room temperature for 24 hours to prepare an oxidized form, and immediately before the experiment, dissolved APO was treated with DTT to prepare a reduced form. Cells treated with each molecule for the indicated times were lysed, analyzed by non-reducing or reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then investigated with specific antibodies (Experimental Methods 1-6).
[0075] As a result, it was confirmed that the intensity of the MLKL tetramer and octamer bands decreased when oxidized APO was treated, but there was no change when reduced APO was treated (Figure 6a). This confirmed that the oxidation of APO inhibits MLKL oligomerization, and to confirm that this occurs due to increased binding with MLKL depending on the degree of APO oxidation, the interaction pattern of MLKL and APO due to the oxidation reaction was analyzed by SPR (Experimental Method 1-10).
[0076] As a result, the binding of MLKL protein to oxidized APO was 4.998E-9M, that of reduced APO was 2.442E-7M (Figure 6b), and that of MLKL N-term domain to oxidized APO was 1.312E-6M, that of reduced APO was 1.14E-3M (Figure 6c). Here, binding of MLKL and MLKL N-term domain proteins immobilized on a CM5 chip to samples at six or more concentrations was analyzed.
[0077] In other words, it was confirmed that the oxidation of APO increases its direct binding to MLKL and inhibits the oligomerization of MLKL.
[0078] Experimental Example 9: Confirmation of apomorphine's improvement in DSS-induced colitis To confirm the effects of APO in vivo, a mouse model of DSS-induced colitis was performed, which mimics the symptoms of human colitis. The alleviation of colitis symptoms in mice was measured daily by body weight and DAI score, and was compared by measuring colon length, H&E, PAS staining, immune response, and mucosal barrier damage in mice after completion of the treatment.
[0079] As shown in Figure 7a, mice in the DSS group showed damage to crypt structure, infiltration of inflammatory cells, and submucosal edema due to colitis. Mucus material was also significantly reduced in PAS staining, indicating a significant reduction in colonic mucus secretion, which is commonly observed in IBD patients. In the groups injected with 0.15, 1.5, and 15 mg / kg APO, the characteristic symptoms of colitis, which can be observed in H&E and PAS staining, were alleviated in a concentration-dependent manner. APO treatment was further shown to reduce the HI score (Figure 7a), the amount of colon shortening (Figure 7b), and the DAI score (Figure 7c).
[0080] In summary, the deleterious effects of DSS treatment were ameliorated by APO treatment in a concentration-dependent manner, without any difference due to APO treatment alone, indicating that APO has a protective effect against DSS-induced colitis.
Claims
1. A pharmaceutical composition for preventing or treating a necroptosis-associated disease, comprising apomorphine or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable carrier.
2. 2. The pharmaceutical composition according to claim 1, wherein apomorphine binds to MLKL (mixed lineage kinase domain like pseudokinase) and inhibits oligomerization.
3. The necroptosis-related diseases include stroke, autoimmune disease, inflammatory bowel disease (IBD), sepsis, chronic obstructive pulmonary disease, acute respiratory distress disorder, transfusion-related acute lung injury, transplant rejection, atherosclerosis, aortic aneurysm, and chronic obstructive pulmonary disease (COPD).
2. The pharmaceutical composition of claim 1, wherein the cause of the disease is selected from the group consisting of acute myocardial infarction, terminal ileitis, acute kidney injury, renal ischemia-reperfusion injury, liver injury, steatohepatitis, pancreatitis, and bone marrow failure.
4. The pharmaceutical composition of claim 3, wherein the necroptosis-associated disease is inflammatory bowel disease.
5. 5. The pharmaceutical composition of claim 4, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
6. 2. The pharmaceutical composition of claim 1, wherein the pharma- ceutically acceptable salt is selected from the group consisting of inorganic acid salts, organic acid salts, amino acid salts, sulfonate salts, metal salts and ammonium ion salts.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises apomorphine hydrochloride.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is an injectable preparation.
9. The pharmaceutical composition of claim 7, wherein the injection comprises at least one selected from the group consisting of sodium metabisulfite, benzyl alcohol, hydrochloric acid, and sodium hydroxide.
Citation Information
Patent Citations
Apomorphine hydrochloride medicine composition and ventricular remodeling function thereof
CN105753879A
Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
US20210283217A1
Crystalline form of s-apomorphine
US20210214310A1
Aporphine and oxoaporphine compounds and pharmaceutical use thereof
US7294715B2
